CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
University of Texas Southwestern Medical Center
BeOne Medicines
Lyell Immunopharma, Inc.
Children's Hospital of Philadelphia
Roswell Park Cancer Institute
Innate Pharma
Bristol-Myers Squibb
Janssen Research & Development, LLC
University of Pittsburgh
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Hoffmann-La Roche
Artiva Biotherapeutics, Inc.
AstraZeneca
National Institutes of Health Clinical Center (CC)
Vironexis Biotherapeutics Inc.
Galapagos NV
National Institutes of Health Clinical Center (CC)
University of Chicago
University of California, San Diego
Genmab
Cho Pharma Inc.
Hoffmann-La Roche
Bristol-Myers Squibb
Children's Oncology Group
Medical College of Wisconsin
National Institutes of Health Clinical Center (CC)
Celgene
Essen Biotech
Werewolf Therapeutics, Inc.
University of Alberta
National Research Center for Hematology, Russia
Merck Sharp & Dohme LLC
Incyte Corporation
Eli Lilly and Company
University of Michigan Rogel Cancer Center
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
CellCentric Ltd.
Incyte Corporation
M.D. Anderson Cancer Center
Acerta Pharma BV
CRISPR Therapeutics
Ipsen
Washington University School of Medicine
CRISPR Therapeutics
Bristol-Myers Squibb
Incyte Corporation
University of Texas Southwestern Medical Center